Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

InspireMD, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MS. KENNEDY RETURNS TO INSPIREMD HAVING PREVIOUSLY SERVED AS SALES DIRECTOR SUPPORTING THE INITIAL U.S. LAUNCH OF CGUARD PRIME MS. KENNEDY RETURNS TO INSPIREMD HAVING PREVIOUSLY SERVED AS SALES DIRECTOR SUPPORTING THE INITIAL U.S. LAUNCH OF CGUARD PRIME

INSPIREMD APPOINTS CAROTID INTERVENTION COMMERCIAL LEADER KATHLEEN KENNEDY AS SENIOR VICE PRESIDENT OF GLOBAL SALES AND MARKETING

MIAMI, JUNE 12, 2026 (GLOBE NEWSWIRE) -- INSPIREMD, INC. (NASDAQ: NSPR) (INSPIREMD OR THE COMPANY), DEVELOPER OF THE CGUARD PRIME CAROTID STENT SYSTEM FOR THE PREVENTION OF STROKE, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF INSPIREMD'S BOARD OF DIRECTORS APPROVED INDUCEMENT GRANTS TO SIX (6) NEW NON-EXECUTIVE EMPLOYEES IN THE AGGREGATE AMOUNT OF 91,161 SHARES OF RESTRICTED STOCK (THE INDUCEMENT GRANTS) OUTSIDE OF INSPIREMD'S 2021 EQUITY INCENTIVE PLAN, WITH A GRANT DATE AS OF JUNE 12, 2026, AS AN INDUCEMENT MATERIAL TO THE NON-EXECUTIVE EMPLOYEES ENTERING INTO EMPLOYMENT WITH INSPIREMD, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE INDUCEMENT GRANTS WERE GRANTED UNDER THE INSPIREMD'S 2024 INDUCEMENT PLAN, WHICH IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY EMPLOYEES OF INSPIREMD, OR FOLLOWING A BONA FIDE PERIOD OF NON-EMPLOYMENT, AS AN INDUCEMENT MATERIAL TO SUCH INDIVIDUALS ENTERING INTO EMPLOYMENT WITH INSPIREMD, PURSUANT TO NASDAQ LISTING RULE 5635(C)(4).

INSPIREMD ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

MIAMI, JUNE 11, 2026 (GLOBE NEWSWIRE) -- INSPIREMD, INC. (NASDAQ: NSPR) (INSPIREMD OR THE COMPANY), DEVELOPER OF THE CGUARD PRIME CAROTID STENT SYSTEM FOR THE PREVENTION OF STROKE, TODAY ANNOUNCED 30-DAY OUTCOMES FROM THE CGUARDIANS II CLINICAL TRIAL OF THE CGUARD PRIME 80CM IMPLANT FOR USE IN TRANSCAROTID ARTERY REVASCULARIZATION (TCAR) PROCEDURES. INSPIREMD ANTICIPATES POTENTIAL APPROVAL OF THE CGUARD PRIME 80 CM STENT IMPLANT IN THE SECOND HALF OF THIS YEAR.

INSPIREMD ANNOUNCES 30-DAY RESULTS FROM THE CGUARDIANS II CLINICAL TRIAL OF THE CGUARD PRIME 80 CM IMPLANT FOR USE IN TCAR PROCEDURES

MIAMI, JUNE 08, 2026 (GLOBE NEWSWIRE) -- INSPIREMD, INC. (NASDAQ: NSPR) (INSPIREMD OR THE COMPANY), DEVELOPER OF THE CGUARD PRIME CAROTID STENT SYSTEM FOR THE PREVENTION OF STROKE, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN ENROLLED IN THE CGUARDIANS III PIVOTAL STUDY OF ITS SWITCHGUARD NEURO PROTECTION SYSTEM (NPS), FOR USE WITH ITS CGUARD PRIME 80 CM STENT PLATFORM, IN TRANSCAROTID ARTERY REVASCULARIZATION (TCAR) PROCEDURES. THE PATIENT WAS ENROLLED BY DR. PATRICK MUCK AT GOOD SAMARITAN HOSPITAL, PART OF THE TRIHEALTH SYSTEM IN CINCINNATI, OHIO.

INSPIREMD ANNOUNCES FIRST PATIENT ENROLLED IN THE CGUARDIANS III PIVOTAL STUDY OF THE SWITCHGUARD NEURO PROTECTION SYSTEM FOR USE IN TCAR PROCEDURES

MIAMI, MAY 06, 2026 (GLOBE NEWSWIRE) -- INSPIREMD, INC. (NASDAQ: NSPR) (INSPIREMD OR THE COMPANY), DEVELOPER OF THE CGUARD PRIME CAROTID STENT SYSTEM FOR THE PREVENTION OF STROKE, TODAY ANNOUNCED PLANS TO PRESENT AT THE UPCOMING BANK OF AMERICA SECURITIES 2026 GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, MAY 13TH AT 4:20 PM PACIFIC TIME (PT). A LIVE AUDIO WEBCAST AND AN ARCHIVE OF THE RECORDING WILL BE AVAILABLE THROUGH THE INVESTORS PAGE OF INSPIREMD'S CORPORATE WEBSITE AT HTTPS://INVESTORS.INSPIREMD.COM.

INSPIREMD TO PARTICIPATE IN UPCOMING BANK OF AMERICA SECURITIES 2026 GLOBAL HEALTHCARE CONFERENCE

- REPORTS TOTAL Q1 2026 REVENUE OF $3.4 MILLION, REPRESENTING YEAR-OVER-YEAR GROWTH OF 122% - - RECEIVED IDE APPROVAL FROM FDA TO INITIATE THE CGUARDIANS III CLINICAL TRIAL OF ITS SWITCHGUARD NEURO PROTECTION SYSTEM FOR USE IN TCAR PROCEDURES - - FDA APPROVAL OF THE ORIGINAL CGUARD DELIVERY SYSTEM ANTICIPATED IN Q3 2026 - - ON TRACK FOR EXPECTED FDA APPROVAL OF THE CGUARD PRIME 80 CM FOR TCAR PROCEDURES IN H2 2026, POTENTIALLY DOUBLING THE COMPANY'S ADDRESSABLE MARKET - MIAMI, MAY 04, 2026 (GLOBE NEWSWIRE) -- INSPIREMD, INC. (NASDAQ: NSPR) (INSPIREMD OR THE COMPANY), DEVELOPER OF THE CGUARD PRIME CAROTID STENT SYSTEM FOR THE PREVENTION OF STROKE, TODAY ANNOUNCED FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. RECENT BUSINESS HIGHLIGHTS: GENERATED REVENUE OF $3.4 MILLION IN THE FIRST QUARTER OF 2026, UP 122% YEAR-OVER-YEAR, WITH SIGNIFICANT GROWTH IN DEMAND FOR CGUARD PRIME IN THE U.S. AND ORIGINAL CGUARD IN INTERNATIONAL MARKETS.

INSPIREMD REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

- STRONG CLINICAL DEMAND CONTINUES IN Q1 2026 WITH GLOBAL YEAR-OVER-YEAR UNIT SALES GROWTH OF 53% AND QUARTER-OVER-QUARTER U.S. UNIT SALES GROWTH OF 34% -

INSPIREMD INITIATES VOLUNTARY U.S. RECALL OF CGUARD PRIME 135 CM CAROTID STENT DELIVERY SYSTEM

MIAMI, APRIL 27, 2026 (GLOBE NEWSWIRE) -- INSPIREMD, INC. (NASDAQ: NSPR), DEVELOPER OF THE CGUARD PRIME CAROTID STENT SYSTEM FOR THE PREVENTION OF STROKE, TODAY ANNOUNCED THAT IT WILL RELEASE ITS FIRST QUARTER FINANCIAL RESULTS ON MONDAY, MAY 4, 2026. IN CONJUNCTION WITH THE RELEASE, INSPIREMD WILL HOST A CONFERENCE CALL AND WEBCAST AT 4:30 P.M. EASTERN TIME TO DISCUSS ITS FINANCIAL RESULTS AND RECENT HIGHLIGHTS.

INSPIREMD TO ANNOUNCE FIRST QUARTER 2026 FINANCIAL RESULTS

MIAMI, MARCH 31, 2026 (GLOBE NEWSWIRE) -- INSPIREMD, INC. (NASDAQ: NSPR), DEVELOPER OF THE CGUARD PRIME CAROTID STENT SYSTEM FOR THE PREVENTION OF STROKE, TODAY ANNOUNCED PLANS TO PRESENT AT THE UPCOMING 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON TUESDAY, APRIL 14TH AT 12:45 PM EASTERN TIME (ET).

INSPIREMD TO PARTICIPATE IN UPCOMING 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

MIAMI, MARCH 18, 2026 (GLOBE NEWSWIRE) -- INSPIREMD, INC. (NASDAQ: NSPR) (INSPIREMD OR THE COMPANY), DEVELOPER OF THE CGUARD PRIME CAROTID STENT SYSTEM FOR THE PREVENTION OF STROKE, TODAY ANNOUNCED FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2025. RECENT BUSINESS HIGHLIGHTS: GENERATED REVENUE OF $3.1 MILLION IN THE FOURTH QUARTER OF 2025, UP 62% YEAR-OVER-YEAR.

InspireMD, Inc.

NSPR

Price

Financial Reports

No items found.

Press Releases

InspireMD, Inc.

NSPR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NSPR